NetWorth
LeaderPortfolio
family
Thomas Struengmann & family
Rank #305
GERMANY•Healthcare•Pharmaceuticals

Thomas Struengmann & family

Net Worth
$10.746B
-0.17% (24h)
Thomas Strüngmann, a prominent German entrepreneur and investor, is known for his significant contributions to the pharmaceutical and biotechnology industries. Born in 1950, he earned an MBA from the University of Augsburg and co-founded Hexal AG, a leading generic drug manufacturer, with his twin brother Andreas. Their strategic investments, including an early stake in BioNTech, have significantly contributed to their wealth, especially through the development of the COVID-19 vaccine. With an estimated net worth of $11.8 billion, the Strüngmann family is ranked among the wealthiest in Germany, and they are actively involved in philanthropy and healthcare advancements.

How to read Thomas Struengmann & family's profile

Public net-worth figures are estimates. They combine observable inputs—typically listed equity, disclosed transactions, and market prices—with editorial judgment where filings are incomplete (for example, private holdings, debt, or cross-holdings). For Thomas Struengmann & family, we anchor the narrative to Pharmaceuticals and Pharmaceuticals, then update the headline number as markets move. The chart on this page is meant to show trajectory, not a certified balance sheet.

When you see $10.746B alongside global rank #305, interpret it as our best synthesis of widely cited ownership and price signals—not a claim about cash on hand. Estimates can diverge from other publishers because of different treatment of options, trusts, charitable vehicles, or illiquid assets. We document the general approach in methodology and welcome corrections via corrections.

Country (GERMANY) and career milestones on this page are curated for reader context; they should be verified against primary sources when used for research. Editorial metadata for this profile is refreshed on a rolling basis, with deeper audits at least annually (last noted cycle: 2026).

Looking for depth? When available, the dossier and timeline sections below add long-form context beyond the headline number—prioritize those modules when evaluating claims about strategy, controversies, or philanthropic commitments.

The Full Dossier

Early Life and Career

Thomas Strüngmann was born in Mülheim an der Ruhr, Germany, on February 16, 1950. He earned a degree in Business Administration from the University of Augsburg. Together with his twin brother Andreas, he took over their father's pharmaceutical company, Durachemie, in 1979, gaining valuable industry experience.

Rise to Success

In 1986, the Strüngmann brothers co-founded Hexal AG, focusing on generic pharmaceuticals. Under their leadership, Hexal became a leading generic drug manufacturer in Germany. They sold Hexal and their stake in Eon Labs to Novartis in 2005 for approximately $7 billion. Post-Hexal, they established investment firms like Santo Holding and Athos Service, concentrating on biotech and healthcare.

Key Business Strategies

The Strüngmann brothers are known for their strategic investments in the pharmaceutical and biotechnology industries. A pivotal move was their early investment in BioNTech in 2008, providing seed funding of €136.5 million. This investment proved highly successful due to BioNTech's partnership with Pfizer to develop the COVID-19 vaccine. They continue to be major shareholders in BioNTech.

Philanthropy

Beyond their business ventures, Thomas and Andreas founded the Ernst Strüngmann Institute in 2008, a neuroscience research center in Frankfurt named after their father, demonstrating their commitment to scientific advancement.

Career Timeline

2008

Invested in BioNTech

Made a significant early investment in BioNTech, which contributed to the development of the COVID-19 vaccine.

2005

Sold Hexal to Novartis

Sold Hexal and their stake in Eon Labs to Novartis for approximately $7 billion.

1986

Co-founded Hexal AG

Co-founded Hexal AG, which focused on generic pharmaceuticals and became a leading drug manufacturer in Germany.

1979

Took over Durachemie

Thomas and Andreas Strüngmann took over their father's pharmaceutical company, Durachemie, gaining industry experience.

Philanthropic Impact

Scientific ResearchUndisclosed

Ernst Strüngmann Institute

Founded the Ernst Strüngmann Institute, a neuroscience research center in Frankfurt

Key Business Ventures & Holdings

CompanyStakeValue
BioNTech50.00%—

Net Worth History

In-Depth Analysis

Early Life and Career

Thomas Strüngmann was born in Mülheim an der Ruhr, Germany, on February 16, 1950. He earned a degree in Business Administration from the University of Augsburg. Together with his twin brother Andreas, he took over their father's pharmaceutical company, Durachemie, in 1979, gaining valuable industry experience.

Rise to Success

In 1986, the Strüngmann brothers co-founded Hexal AG, focusing on generic pharmaceuticals. Under their leadership, Hexal became a leading generic drug manufacturer in Germany. They sold Hexal and their stake in Eon Labs to Novartis in 2005 for approximately $7 billion. Post-Hexal, they established investment firms like Santo Holding and Athos Service, concentrating on biotech and healthcare.

Key Business Strategies

The Strüngmann brothers are known for their strategic investments in the pharmaceutical and biotechnology industries. A pivotal move was their early investment in BioNTech in 2008, providing seed funding of €136.5 million. This investment proved highly successful due to BioNTech's partnership with Pfizer to develop the COVID-19 vaccine. They continue to be major shareholders in BioNTech.

Philanthropy

Beyond their business ventures, Thomas and Andreas founded the Ernst Strüngmann Institute in 2008, a neuroscience research center in Frankfurt named after their father, demonstrating their commitment to scientific advancement.

Data Sources & Methodology

Figures for Thomas Struengmann & family are synthesized from the sources below and cross-checked against our net worth methodology. Estimates may lag market moves; see corrections to report discrepancies.

You may also like

HubAll BillionairesHubGlobal RankingsHubNewsroom